Cavallo Luigi M, Solari Domenico, Somma Teresa, Di Somma Alberto, Chiaramonte Carmela, Cappabianca Paolo
Division of Neurosurgery, Department of Neurosciences, Reproductive and Odontostomatological Sciences, Università degli Studi di Napoli Federico II Naples, Italy.
Transl Med UniSa. 2013 Sep 2;7:23-8. eCollection 2013.
The aim of this study was to describe the use of equine pericardium sheet (Lyomesh (®) ) as dural substitute for sellar reconstruction after endoscopic endonasal transsphenoidal surgery for the removal of pituitary adenomas.
We reviewed data of patients that underwent surgery by means of an endoscopic endonasal transsphenoidal approach for the removal of pituitary adenomas over a 12-months period, starting in May 2012, i.e. when we adopted Lyomesh (®) (Audio Technologies, Piacenza, Italy) an equine pericardium sheet, as dura mater substitute.
During the 12-months period evaluated, we performed an endoscopic endonasal transsphenoidal operation for a variety of pituitary lesions on 102 consecutive patients. Among these, in 12 patients (9.4%) harboring a pituitary adenoma, the implant of the pericardium sheet was used. Four patients (33.3%) presented a small intraoperative cerebrospinal fluid (CSF) leak; in these cases the Lyomesh (®) was placed intradurally with fibrin glue and, thereafter, several layers were positioned in extradural space. In 8 other subjects without any evidence of CSF leak, the dural substitute was placed intradurally and fibrin glue was injected intradurally to hold the material in place.
Even if based on a relatively small patient series, our experience demonstrated that the use of equine pericardium sheet (Lyomesh (®) ) as dura mater substitute in transsphenoidal surgery is safe and biocompatible, as compared with other dural substitutes.
本研究旨在描述在经鼻内镜下经蝶窦手术切除垂体腺瘤后,使用马心包片(Lyomesh®)作为硬脑膜替代物进行鞍区重建的情况。
我们回顾了2012年5月开始的12个月期间,通过经鼻内镜下经蝶窦入路手术切除垂体腺瘤的患者数据,即从我们采用马心包片(Lyomesh®,意大利皮亚琴察的Audio Technologies公司生产)作为硬脑膜替代物时开始。
在评估的12个月期间,我们对102例连续患者进行了经鼻内镜下经蝶窦手术治疗各种垂体病变。其中,12例(9.4%)患有垂体腺瘤的患者使用了心包片植入。4例(33.3%)患者术中出现少量脑脊液漏;在这些病例中,将Lyomesh®置于硬脑膜内并用纤维蛋白胶固定,然后在硬脑膜外间隙放置几层。另外8例无脑脊液漏证据的患者,将硬脑膜替代物置于硬脑膜内,并向硬脑膜内注射纤维蛋白胶以固定材料。
即使基于相对较小的患者系列,我们的经验表明,与其他硬脑膜替代物相比,在经蝶窦手术中使用马心包片(Lyomesh®)作为硬脑膜替代物是安全且具有生物相容性的。